Equities research analysts expect Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to announce earnings per share of $0.12 for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Pacira Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at $0.25. Pacira Pharmaceuticals posted earnings of $0.09 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 33.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Pacira Pharmaceuticals will report full-year earnings of ($0.07) per share for the current financial year, with EPS estimates ranging from ($0.29) to $0.09. For the next year, analysts anticipate that the company will report earnings of $0.62 per share, with EPS estimates ranging from ($0.47) to $1.56. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same period last year, the business posted $0.20 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year.
Several research analysts have recently issued reports on PCRX shares. CIBC started coverage on Pacira Pharmaceuticals in a research note on Thursday, September 7th. They issued a “market perform” rating for the company. UBS Group started coverage on Pacira Pharmaceuticals in a research note on Wednesday, September 6th. They issued a “market perform” rating for the company. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 price objective on shares of Pacira Pharmaceuticals in a research note on Tuesday, September 5th. Zacks Investment Research cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 9th. Finally, Bank of America reduced their price objective on Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $48.73.
Shares of Pacira Pharmaceuticals (PCRX) traded down $0.30 during trading hours on Wednesday, hitting $45.10. The stock had a trading volume of 317,934 shares, compared to its average volume of 824,210. Pacira Pharmaceuticals has a 1 year low of $29.81 and a 1 year high of $58.95. The stock has a market capitalization of $1,840.00, a PE ratio of -34.43 and a beta of 2.20. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.
In other Pacira Pharmaceuticals news, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $41.11, for a total value of $34,943.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,075 shares of company stock worth $2,707,452. 6.60% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. boosted its stake in shares of Pacira Pharmaceuticals by 5.2% in the second quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock worth $261,000 after acquiring an additional 270 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after acquiring an additional 302 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Pacira Pharmaceuticals by 12.7% in the second quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock worth $240,000 after acquiring an additional 566 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Pacira Pharmaceuticals by 5.3% in the second quarter. Legal & General Group Plc now owns 12,985 shares of the company’s stock worth $620,000 after acquiring an additional 653 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Pacira Pharmaceuticals by 2.2% in the second quarter. California Public Employees Retirement System now owns 64,700 shares of the company’s stock worth $3,086,000 after acquiring an additional 1,400 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/11/pacira-pharmaceuticals-inc-pcrx-expected-to-announce-earnings-of-0-12-per-share.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.